---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-22-000008"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2022-02-25T23:59:59+00:00"
generated_at: "2026-06-27T04:21:37.907179+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Caladrius Biosciences Chief Legal Officer Todd Girolamo resigns effective March 14

## Summary
- Todd Girolamo resigns as Chief Legal Officer, SVP Corporate Development, and Corporate Secretary.
- Resignation effective March 14, 2022; reason is to pursue other career opportunities.
- No replacement named as of the filing date.

## SEC filing metadata
- accession: 0000320017-22-000008
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2022-02-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001722000008/0000320017-22-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001722000008/clbs-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-22-000008
- JSON: https://secwatch.observer/filing/0000320017-22-000008.json
- Plain text: https://secwatch.observer/filing/0000320017-22-000008.txt

## Key facts
- Executive change
  Todd C. Girolamo resigned as Chief Legal Officer at LISATA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Chief Legal Officer
  source text: On February 24, 2022, Todd C. Girolamo, Esq., Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc. (the “Company”), notified the Company of his intent to resign from all positions held with the Company in order to pursue other career opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001722000008/0000320017-22-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.